SEC Form 4	
------------	--

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per response:	0.5				

7

Section obligati	this box if no lo 16. Form 4 or ons may contin ion 1(b).	Form 5	STA			oursua	nt to S	HANGE Section 16(a 30(h) of the	a) of the S	Securi	ties Exch	ange A	Act of 19		SHI	Ρ	Estim	Number ated ave per resp	erage burde	3235-0287 n 0.5
				2. Issuer Name <b>and</b> Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					wner		
				3. Date of Earliest Transaction (Month/Day/Year) 06/21/2019									Officer (give title Other (specify below) below)							
			4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person								
(City)	(S	tate)	(Zip)																	
		т	able I - No	n-De	rivat	ive S	ecu	rities Ac	quired	, Dis	posed	of, c	or Ben	eficia	lly O	wned				
1. Title of S	Security (Inst	r. 3)		2. Transacti Date (Month/Day			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. ) 8)						and 5) Securities Beneficiall Owned Fol		у	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amour	t	(A) or (D)		e	Reported Transaction (Instr. 3 and				(Instr. 4)
Common	Stock			06/	/21/2	1/2019			C <sup>(1)</sup>		4,980	,980,168 A		\$(	0 <sup>(1)</sup>	4,980,	,168	<b>D</b> <sup>(2)</sup>		
Common	Stock			06/	/21/2	/2019			<b>C</b> <sup>(1)</sup>		7,617	7,617,746 A		\$(	0(1)	12,597,914		<b>D</b> <sup>(2)</sup>		
Common	Stock			06/	/21/2	/2019			<b>C</b> <sup>(1)</sup>		2,799	2,799,910 A		\$(	0(1)	15,397,824		<b>D</b> <sup>(2)</sup>		
Common	Common Stock 06/21/2		/21/2	/2019			Р		1,388,889 A		\$	18	16,786,713		<b>D</b> <sup>(2)</sup>					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	(	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			e Securities Under			Underlyi Security	ing	8. Price of Derivative Security (Instr. 5)	derivativ Securitie Benefici Owned Followin Reporte	curities neficially vned llowing ported	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiratio Date	n Titl		Amount Number Shares			Transac (Instr. 4)			
Series A Convertible Preferred Stock	(1)	06/21/2019			C <sup>(1)</sup>			4,980,168	(1)		(1)		mmon tock	4,980,3	168	\$0	0		D <sup>(2)</sup>	
Series A-2 Convertible Preferred Stock	(1)	06/21/2019			C <sup>(1)</sup>			7,617,746	(1)		(1)		mmon tock	7,617,	746	\$0	0		D <sup>(2)</sup>	
Series B Convertible Preferred Stock	(1)	06/21/2019			C <sup>(1)</sup>			2,799,910	(1)		(1)		mmon tock	2,799,9	910	\$0	0		D <sup>(2)</sup>	
1. Name and Address of Reporting Person* <u>Apple Tree Partners IV, L.P.</u>																				
(Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE																				
(Street) BEDFOF	2D	МА	01730	)																
(City)		(State)	(Zip)																	
	d Address of <u>GP, Ltd.</u>	Reporting Person*																		
(Last)		(First)	(Middle	e)																

C/O STOKE THERAPEUTICS, INC. **45 WIGGINS AVENUE** 

(Street) BEDFORD	MA	01730

(City) (State) (Zip)
Explanation of Responses:

1. The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019.

2. Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

<u>/s/ Stephen Tulipano, Attorney-</u> <u>in-Fact</u> <u>06/21/2019</u>

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.